Use of Phase 3 trial samples for RNA NGS kit

• Research type

  Research Study

• Full title

  A non-interventional, retrospective, feasibility study for the testing of RNA extracted from whole blood samples, derived from patients that participated in a phase 3 clinical trial. The therapeutic targets human papillomavirus (HPV). The results from this study will be used to determine if the proposed Next Generation Sequencing (NGS) workflow is compatible with this sample type.

• IRAS ID

  291975

• Contact name

  Jonathan Perkins

• Contact email

  jonathan.perkins@qiagen.com

• Sponsor organisation

  QIAGEN

• Clinicaltrials.gov Identifier

  n/a, n/a

• Duration of Study in the UK

  1 years, 6 months, 1 days

• Research summary

  QIAGEN have partnered with a Pharma Partner to develop a medical diagnostic that may detect important RNAs in patients with pre-cancerous lesions due to Human Papilloma Virus (HPV) infection. This is done in order to improve treatment of the pre-cancerous lesions, detection of the RNAs can help to inform treatment with a drug from the Pharma Partner.

• REC name

  London - Camberwell St Giles Research Ethics Committee

• REC reference

  20/PR/0860

• Date of REC Opinion

  30 Dec 2020

• REC opinion

  Further Information Favourable Opinion